Association of SGLT2 inhibitors and urogenital infections in patients attending a tertiary care hospital: a prospective observational study

Simple item page
dc.contributor.authorBenoy, Aen_US
dc.contributor.authorJoseph, Men_US
dc.contributor.authorSabu, JEen_US
dc.contributor.authorBijuraj, PRAen_US
dc.contributor.authorMathew, Sen_US
dc.contributor.authorVarghese, TDen_US
dc.contributor.authorJoy, Ven_US
dc.contributor.authorPunnose, Een_US
dc.contributor.authorFischer, Len_US
dc.date.accessioned2025-06-18T11:13:49Z
dc.date.available2025-06-18T11:13:49Z
dc.date.issued2025-02
dc.description.abstractBackground: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are known for efficacy in managing blood sugar levels in type 2 diabetes and also improving cardiovascular and renal outcomes. However, increased risk of urogenital infections (UGIs) remains a significant concern in their safety profile. This study aimed to investigate the association between SGLT2i therapy and UGIs in a real-world clinical set up of a tertiary care centre in India. The key hypothesis was SGLT2i use is associated with incidence of UGIs while the secondary hypothesis included the relationship of the incidence of risk with the dose. Methods: This was a six-month prospective observational study, that enrolled 309 adults ?18 years of age, who were newly prescribed SGLT2 inhibitors, particularly Dapagliflozin 5 mg and 10 mg from October 2023. The incidence of UGIs was assessed through patient interviews and medical records during the follow up from 2 weeks of initiation. UGIs were defined as clinical manifestations that resolved on SGLT2i discontinuation or appropriate treatment. Results: Of 309 initiators, 300 patients were followed up. 9 patients didnꊰ follow up in OPD. From these, 58 (19.3%) patients developed UGIs, comprising of 47 (15.6%) bacterial infections and 11 (3.6%) UGIs of fungal origin. The association was performed on basis of logistic regression analysis which revealed a statistically significant association of UGIs with the prescription of SGLT2i. Higher doses of SGLT2 inhibitors was observed to be associated with significantly increasing the risk of UGIs (p<0.05). No significant risk factors such as body mass index (BMI), age, sex, HbA1c or educational status were identified to have significant associations with UGI occurrence. Conclusions: This study highlights a clinically relevant association between SGLT2i use and urogenital infections.en_US
dc.identifier.affiliationsDepartment of Pharmacy Practice, Nirmala College of Pharmacy, Muvattupuzha, Kerala, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacy Practice, Nirmala College of Pharmacy, Muvattupuzha, Kerala, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacy Practice, Nirmala College of Pharmacy, Muvattupuzha, Kerala, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacy Practice, Nirmala College of Pharmacy, Muvattupuzha, Kerala, Indiaen_US
dc.identifier.affiliationsDepartment of Pharmacy Practice, Nirmala College of Pharmacy, Muvattupuzha, Kerala, Indiaen_US
dc.identifier.affiliationsDepartment of Cardiology, MOSC Medical College Hospital Kolencherrry, Kerala, Indiaen_US
dc.identifier.affiliationsDepartment of Cardiology, MOSC Medical College Hospital Kolencherrry, Kerala, Indiaen_US
dc.identifier.affiliationsDepartment of Cardiology, MOSC Medical College Hospital Kolencherrry, Kerala, Indiaen_US
dc.identifier.affiliationsDepartment of Cardiology, MOSC Medical College Hospital Kolencherrry, Kerala, Indiaen_US
dc.identifier.citationBenoy A, Joseph M, Sabu JE, Bijuraj PRA, Mathew S, Varghese TD, Joy V, Punnose E, Fischer L. Association of SGLT2 inhibitors and urogenital infections in patients attending a tertiary care hospital: a prospective observational study. International Journal of Advances in Medicine. 2025 Feb; 12(1): 50-56en_US
dc.identifier.issn2349-3925
dc.identifier.issn2349-3933
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/248373
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber1en_US
dc.relation.volume12en_US
dc.source.urihttps://doi.org/10.18203/2349-3933.ijam20243814en_US
dc.subjectBlood sugaren_US
dc.subjectDapagliflozinen_US
dc.subjectDiabetesen_US
dc.subjectHbA1cen_US
dc.subjectMycotic infectionsen_US
dc.subjectOral Hypoglycaemicsen_US
dc.subjectSGLT2 inhibitorsen_US
dc.subjectUrogenital infectionsen_US
dc.subjectUGIen_US
dc.subjectBacteriuriaen_US
dc.subjectUrethritisen_US
dc.titleAssociation of SGLT2 inhibitors and urogenital infections in patients attending a tertiary care hospital: a prospective observational studyen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijam2025v12n1p50.pdf
Size:
275.21 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Advances in Medicine